image
Healthcare - Medical - Instruments & Supplies - NYSE - US
$ 130.69
-0.94 %
$ 5.84 B
Market Cap
87.71
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TFX stock under the worst case scenario is HIDDEN Compared to the current market price of 131 USD, Teleflex Incorporated is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TFX stock under the base case scenario is HIDDEN Compared to the current market price of 131 USD, Teleflex Incorporated is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TFX stock under the best case scenario is HIDDEN Compared to the current market price of 131 USD, Teleflex Incorporated is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TFX

image
$240.0$240.0$220.0$220.0$200.0$200.0$180.0$180.0$160.0$160.0$140.0$140.0$120.0$120.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
3.05 B REVENUE
2.45%
151 M OPERATING INCOME
-70.17%
69.7 M NET INCOME
-80.45%
636 M OPERATING CASH FLOW
24.50%
-99.4 M INVESTING CASH FLOW
84.01%
-422 M FINANCING CASH FLOW
-1094.77%
795 M REVENUE
4.06%
-110 M OPERATING INCOME
-73.93%
-137 M NET INCOME
-123.11%
202 M OPERATING CASH FLOW
-12.34%
-23.1 M INVESTING CASH FLOW
-8.75%
-119 M FINANCING CASH FLOW
31.86%
Balance Sheet Teleflex Incorporated
image
Current Assets 1.47 B
Cash & Short-Term Investments 290 M
Receivables 459 M
Other Current Assets 721 M
Non-Current Assets 5.63 B
Long-Term Investments 0
PP&E 612 M
Other Non-Current Assets 5.02 B
4.09 %6.47 %10.16 %8.62 %70.65 %Total Assets$7.1b
Current Liabilities 649 M
Accounts Payable 141 M
Short-Term Debt 100 M
Other Current Liabilities 408 M
Non-Current Liabilities 2.17 B
Long-Term Debt 1.66 B
Other Non-Current Liabilities 515 M
5.00 %3.55 %14.48 %58.69 %18.28 %Total Liabilities$2.8b
EFFICIENCY
Earnings Waterfall Teleflex Incorporated
image
Revenue 3.05 B
Cost Of Revenue 1.34 B
Gross Profit 1.7 B
Operating Expenses 1.56 B
Operating Income 151 M
Other Expenses 81.3 M
Net Income 69.7 M
4b4b3b3b3b3b2b2b2b2b1b1b500m500m003b(1b)2b(2b)151m(81m)70mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
55.87% GROSS MARGIN
55.87%
4.96% OPERATING MARGIN
4.96%
2.29% NET MARGIN
2.29%
1.63% ROE
1.63%
0.98% ROA
0.98%
2.14% ROIC
2.14%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Teleflex Incorporated
image
600m600m500m500m400m400m300m300m200m200m100m100m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 69.7 M
Depreciation & Amortization 275 M
Capital Expenditures -126 M
Stock-Based Compensation 31.3 M
Change in Working Capital -1.82 M
Others 277 M
Free Cash Flow 509 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Teleflex Incorporated
image
Wall Street analysts predict an average 1-year price target for TFX of $234 , with forecasts ranging from a low of $149 to a high of $275 .
TFX Lowest Price Target Wall Street Target
149 USD 14.01%
TFX Average Price Target Wall Street Target
234 USD 78.67%
TFX Highest Price Target Wall Street Target
275 USD 110.42%
Price
Max Price Target
Min Price Target
Average Price Target
280280260260240240220220200200180180160160140140120120May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.19% DIVIDEND YIELD
0.34 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.401.401.201.201.001.000.800.800.600.600.400.400.200.200.000.000.340.340.340.340.340.340.340.340.340.340.340.340.340.340.340.340.340.340.340.340.340.340.340.340.340.340.340.340.340.340.340.341.360.341.360.341.360.341.360.341.360.341.360.341.360.341.360.341.360.341.360.342015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Teleflex Incorporated
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
639 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX NEW YORK CITY, NY / ACCESS Newswire / April 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX NEW YORK CITY, NY / ACCESS Newswire / April 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Teleflex Incorporated (“Teleflex” or the “Company”) (NYSE: TFX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. globenewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 weeks ago
Aurora Spine Announces Publication of Biomechanical Study Demonstrating Superiority of SiLO TFX™ Sacroiliac Fusion System CARLSBAD, California, April 02, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the publication of a new clinical study titled "Fixation of the Sacroiliac Joint: A Cadaver-Based Concurrent-Controlled Biomechanical Comparison of Posterior Interposition and Posterolateral Transosseous Techniques" in the journal Neurospine. The study evaluates the biomechanical performance of Aurora Spine's SiLO TFX™ MIS Sacroiliac Joint Fixation System compared to traditional posterolateral transosseous techniques.​ globenewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 weeks ago
Teleflex Receives FDA 510(k) Clearance of the AC3 Range™ Intra-Aortic Balloon Pump (IABP) The addition to the IABP family supports uncompromised cardiac support for patients during transport The addition to the IABP family supports uncompromised cardiac support for patients during transport globenewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX NEW YORK , March 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE: TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Teleflex Incorporated (“Teleflex” or the “Company”) (NYSE: TFX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. globenewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX NEW YORK CITY, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 weeks ago
Preliminary Results from IDE Study on Ringer™ Perfusion Balloon Catheter (PBC) Reported from Podium at CTO Plus Conference WAYNE, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the preliminary results from its Ringer™ PBC IDE study were reported in a featured presentation at the CTO Plus Conference in New York by the study's principal investigator, David E. Kandzari, MD, FACC, MSCAI, Chief, Piedmont Heart Institute and Cardiovascular Services, Chief Scientific Officer and Director, Interventional Cardiology at Piedmont Heart Institute, Atlanta, GA. globenewswire.com - 3 weeks ago
8. Profile Summary

Teleflex Incorporated TFX

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 5.84 B
Dividend Yield 0.19%
Description Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Contact 550 East Swedesford Road, Wayne, PA, 19087-1603 https://www.teleflex.com
IPO Date March 17, 1980
Employees 14100
Officers Mr. Jake Newman President of The Americas Mr. Timothy F. Duffy Vice President & Chief Information Officer Mr. James Ferguson President & GM of Surgical Mr. Jay K. White Corporate Vice President & President of Global Commercial Mr. Howard Cyr Corporate Vice President & Chief Compliance Officer Mr. Lawrence Soren Keusch Vice President of Investor Relations & Strategy Development Ms. Michelle Fox Corporate Vice President & Chief Medical Officer Mr. Matthew James President, EMEA & Global Urology Mr. Liam J. Kelly Chairman, President & Chief Executive Officer Mr. Cameron P. Hicks Corporate Vice President & Chief Human Resources Officer